Change in quality of life, enjoyment, and satisfaction total score with CAPLYTA1
Monotherapy: Q-LES-Q-SF total score at week 6*
Limitation: This secondary endpoint was not powered for statistical comparison and is descriptive only. Therefore, the results require cautious interpretation.
CAPLYTA 42 mg (n=169)
Placebo (n=164)
Limitation: This secondary endpoint was not powered for statistical comparison and is descriptive only. Therefore, the results require cautious interpretation.
LSM=least squares mean; Q-LES-Q-SF=Quality of Life Enjoyment and Satisfaction Questionnaire—Short Form.
*The Q-LES-Q-SF (Endicot et al, 1993) is a patient-reported, 14-item questionnaire that uses a 5-point rating scale from very poor to very good to assess patient satisfaction with a variety of items. Scores are summed to provide a raw total score ranging from 14 to 70; the total raw score is converted to a percent score.1 Baseline scores were 37.03 for CAPLYTA and 38.61 for placebo.
Q-LES-Q-SF scale description
The Q-LES-Q-SF asks the patient how satisfied in the past week they are with their1:
- physical health
- mood
- work
- household activities
- social relationships
- family relationships
- leisure time activities
- ability to function in daily life
- sexual drive/interest/performance
- economic status
- living/housing situation
- ability to get around physically without feeling dizzy or unsteady or falling
- vision in terms of ability to do work or hobbies
- overall sense of well-being
- medication satisfaction
- overall life satisfaction
Reference: 1. Riendeau RP, Sullivan JL, Meterko M, et al. Factor structure of the Q-LES-Q short form in an enrolled mental health clinic population. Qual Life Res. 2018;27(11):2953-2964.
Study design
Monotherapy study: 6-week study that randomized 381 patients to either CAPLYTA 42 mg or placebo. Patients were generally moderately to markedly ill. Median age was 45 years (range 18 to 72 years). 58% were female, 91% were Caucasian, and 8% were African American.1 The primary efficacy measure was the change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score.
Full chart description
This graph depicts the change in quality of life as measured by Q-LES-Q-SF total score at 6 weeks for patients receiving CAPLYTA 42 mg or placebo as monotherapy.
See consistent safety data across trials
Helpful tools & resources
Reference: 1. Data on File. 2021.